Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
JAMA|August 10, 2026
Liquid Biopsies for Cancer: A Translational Science ReviewJessica Mezzanotte-Sharpe, Katrina Piemonte, Ben H Park
Breast Cancer Research and Treatment|August 14, 2024
Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trialZihan Melink, Maryam B Lustberg, Patrick M Schnell, et al.
Plos One|December 26, 2025
A research protocol using ECG monitoring for detection of palpitations-associated arrhythmias in breast cancer survivorsYing Sheng, Matthew R Fleming, Jessica Mezzanotte-Sharpe, et al.
Biomedicines|November 27, 2025
Exploratory Analysis of the Impact of a Single Dose of Trastuzumab on the Immune Microenvironment in HER2-Positive Early-Stage Breast CancerNikita Bastin, Jessica Mezzanotte-Sharpe, Rebecca Alvarez, et al.
NPJ Breast Cancer|June 21, 2025
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancerJessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, et al.
Breast Cancer Research and Treatment|July 4, 2025
Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centersJessica Mezzanotte-Sharpe, Chih-Yuan Hsu, David Choi, et al.
Breast Cancer Research and Treatment|July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square|May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Pageof 1